Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · IEX Real-Time Price · USD
54.36
+1.02 (1.91%)
At close: Jul 26, 2024, 4:00 PM
55.44
+1.08 (1.99%)
After-hours: Jul 26, 2024, 6:08 PM EDT
Crinetics Pharmaceuticals Revenue
Crinetics Pharmaceuticals had revenue of $640.00K in the quarter ending March 31, 2024, a decrease of -76.11%. This brings the company's revenue in the last twelve months to $1.97M, down -53.93% year-over-year. In the year 2023, Crinetics Pharmaceuticals had annual revenue of $4.01M, down -15.28%.
Revenue (ttm)
$1.97M
Revenue Growth
-53.93%
P/S Ratio
2,171.63
Revenue / Employee
$6,807
Employees
290
Market Cap
4.29B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alkermes | 1.73B |
RadNet | 1.66B |
Integer Holdings | 1.63B |
Haemonetics | 1.31B |
Inspire Medical Systems | 660.91M |
Apellis Pharmaceuticals | 524.07M |
Ultragenyx Pharmaceutical | 442.59M |
CRISPR Therapeutics AG | 271.71M |
CRNX News
- 8 days ago - Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 - GlobeNewsWire
- 16 days ago - Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner - GlobeNewsWire
- 6 weeks ago - Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly - GlobeNewsWire
- 7 weeks ago - Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D. - GlobeNewsWire
- 2 months ago - Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts - GlobeNewsWire